Home/Pipeline/OcuMet Beacon

OcuMet Beacon

Detection and monitoring of ocular diseases (e.g., diabetic retinopathy, age-related macular degeneration)

ApprovedActive

Key Facts

Indication
Detection and monitoring of ocular diseases (e.g., diabetic retinopathy, age-related macular degeneration)
Phase
Approved
Status
Active
Company

About OcuSciences

OcuSciences is a privately-held medical device company commercializing a functional retinal imaging platform based on its patented OcuMet autofluorescence technology. The technology aims to detect oxidative stress and mitochondrial dysfunction in the eye, offering a potential tool for the early detection and monitoring of diseases like diabetic retinopathy and age-related macular degeneration. Its lead product, the OcuMet Beacon, has received FDA clearance and is positioned for commercialization in the ophthalmology diagnostics market. Founded in 2009 as a spin-out from the University of Michigan, the company is headquartered in Ann Arbor, Michigan.

View full company profile

Therapeutic Areas